title: Expression of the RET receptor tyrosine kinase and GDNFR-alpha in normal and leukemic human hematopoietic cells and stromal cells of the bone marrow microenvironment.
abstract: The RET proto-oncogene product is a receptor tyrosine kinase representing the signal-transducing molecule of a multisubunit surface receptor complex for the glial cell line-derived neurotrophic factor (GDNF), in which a novel glycosyl-phosphatidylinositol (PI)-linked protein (termed GDNFR-alpha) acts as the ligand-binding component. We have analyzed expression of RET and GDNFR-alpha in purified normal hematolymphopoietic cells, leukemia/lymphoma cell lines, and 154 primary samples from patients with hematopoietic malignancies encompassing different lineages and differentiation stages. Relatively low amounts of RET mRNA were found in early CD34+ hematopoietic progenitors, but RET transcripts appeared to increase after myelomonocytic maturation. No expression of RET was found in peripheral blood and tissue B and T lymphocytes. Analysis of human myelomonocytic cell lines was overall consistent with results obtained on purified normal cells. Accordingly, RET expression was mainly confined to acute myeloid leukemias (AMLs) displaying either monocytic (French-American-British M4 and M5) or intermediate-mature myeloid (M2 and M3) phenotypes, being less frequently detected in early myeloid (M0 and M1) AMLs. In contrast, RET mRNA was sporadically detected in B-cell tumors, whereas, among T-cell malignancies, RET transcripts were mainly detected in cells of postthymic and mature T-cell phenotype. RET broad detection in primary tumors was not paralleled by the mutual expression of GDNFR-alpha, which was detected only in 2 isolated primary samples and in 3 leukemia/lymphoma cell lines. However, GDNFR-alpha transcripts, in the absence of RET mRNA, were found in normal bone marrow stromal cells (BMSC), in BM fibroblasts, and in two osteoblast cell lines previously described to support normal hematopoiesis. In the presence of GDNF-receptors derived from BMSC by PI-specific phospholipase C cleavage, GDNF efficiently bound RET-expressing AML blasts and was functionally active by reducing their clonogenic growth and triggering the monocytic maturation of leukemic cells.
authors.affiliation: Divisione di Oncologia Medica, Centro di Riferimento Oncologico, INRCCS, Aviano, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Gattei
authors.forename: A
authors.initials: A
authors.lastname: Celetti
authors.forename: A
authors.initials: A
authors.lastname: Cerrato
authors.forename: M
authors.initials: M
authors.lastname: Degan
authors.forename: A
authors.initials: A
authors.lastname: De Iuliis
authors.forename: F M
authors.initials: FM
authors.lastname: Rossi
authors.forename: G
authors.initials: G
authors.lastname: Chiappetta
authors.forename: C
authors.initials: C
authors.lastname: Consales
authors.forename: S
authors.initials: S
authors.lastname: Improta
authors.forename: V
authors.initials: V
authors.lastname: Zagonel
authors.forename: D
authors.initials: D
authors.lastname: Aldinucci
authors.forename: V
authors.initials: V
authors.lastname: Agosti
authors.forename: M
authors.initials: M
authors.lastname: Santoro
authors.forename: G
authors.initials: G
authors.lastname: Vecchio
authors.forename: A
authors.initials: A
authors.lastname: Pinto
authors.forename: M
authors.initials: M
authors.lastname: Grieco
mesh_terms: D000273:Adipose Tissue / Q000378:metabolism* / Q000473:pathology; D001853:Bone Marrow / Q000378:metabolism* / Q000473:pathology; D003238:Connective Tissue / Q000378:metabolism* / Q000473:pathology; D029721:Drosophila Proteins; D005786:Gene Expression Regulation; D015973:Gene Expression Regulation, Leukemic; D051097:Glial Cell Line-Derived Neurotrophic Factor Receptors; D019337:Hematologic Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D006412:Hematopoietic Stem Cells / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007938:Leukemia / Q000145:classification / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D016131:Lymphocyte Subsets / Q000378:metabolism / Q000473:pathology; D009196:Myeloproliferative Disorders / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D014411:Neoplastic Stem Cells / Q000378:metabolism* / Q000473:pathology; D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis* / Q000235:genetics; D051096:Proto-Oncogene Proteins c-ret; D012333:RNA, Messenger / Q000096:biosynthesis; D012334:RNA, Neoplasm / Q000096:biosynthesis; D020794:Receptor Protein-Tyrosine Kinases / Q000096:biosynthesis* / Q000235:genetics; D014407:Tumor Cells, Cultured
chemical_list: D029721:Drosophila Proteins; D051097:Glial Cell Line-Derived Neurotrophic Factor Receptors; C000715470:MAS1 protein, human; D009363:Neoplasm Proteins; D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D051096:Proto-Oncogene Proteins c-ret; D020794:Receptor Protein-Tyrosine Kinases; C416649:Ret protein, Drosophila